A Phase 2 interventional study of ZT006 and Placebo of ZT006 in Overweight , Obesity, sponsored by Beijing QL Biopharmaceutical Co.,Ltd. Active, not recruiting at 12 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Beijing QL Biopharmaceutical Co.,Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd — 2 open to participants now, 7 under way, 1 of them phase 3. Obesity · Beijing QL Biopharmaceutical Co.,Ltd.
Among the 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd, this one is the 4th largest by enrollment, is the only one that started in 2025, is one of 3 in phase 2, and was the 3rd registered.
11,536 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →2 of the 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd are open now, in 1 country. Recruiting first, the newest first:
Beijing QL Biopharmaceutical Co.,Ltd · Sites in China
Ages 18–75
Beijing QL Biopharmaceutical Co.,Ltd · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2023; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 184 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 77 across the 10 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing QL Biopharmaceutical Co.,Ltd is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
6 of the studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07230119Phase 3Beijing QL Biopharmaceutical Co.,LtdA Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1) | 2027-05-29 |
| NCT07443059Beijing QL Biopharmaceutical Co.,LtdA Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants | 2026-12-03 |
| NCT07550816Beijing QL Biopharmaceutical Co.,LtdDrug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants | 2026-12-05 |
| NCT07230132Beijing QL Biopharmaceutical Co.,LtdEfficacy and Safety of ZT006 in Overweight and Obese Participants | 2026-12-12 |
| NCT07697846Beijing QL Biopharmaceutical Co.,LtdA Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy Adults | 2027-01-13 |
Add all 6 to your calendar (.ics) → With an account.
Among the 10 studies in Obesity by Beijing QL Biopharmaceutical Co.,Ltd, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to evaluate the efficacy and safety of ZT006 tablet in participants with overweight and obesity.
In addition to dietary caloric restriction and increased physical activity, study participants will receive either ZT006 tablets or placebo tablets once every morning (placebo looks like ZT006 tablets but has no active pharmaceutical ingredients). For a fair comparison, study participants are assigned to ZT006 or placebo randomly by a computer.
The study consists of a main study and an extension period. The treatment of the main study will last for 28 weeks. ZT006 tablets will be administered daily in an up-titration fashion, i.e. the dose of ZT006 will be gradually increased to reach three target doses (low, medium, high) so that the participants can tolerate its effect. Participants will have 17 clinic visits including one screening visit and one follow-up visit.
The extension study will be conducted only in participants assigned to the low and medium dose groups in the main study. The treatment of the extension period will be 12 weeks.
Female participants who are pregnant, breast-feeding or who plan to become pregnant during the study are not allowed to participate in the study. Pregnancy will be checked by blood or urine tests during the study.
11,536 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
This study's enrollment of 184 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Browse Obesity studies →Beijing QL Biopharmaceutical Co.,Ltd is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
MAIN STUDY:
Inclusion Criteria:
Exclusion Criteria:
EXTENSION PERIOD:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
administered per os, daily
Drug: ZT006
administered per os, daily
Drug: ZT006
administered per os, daily
Drug: ZT006
administered per os, daily
Drug: Placebo of ZT006
administered per os, weekly
Drug: ZT006
administered per os, weekly
Drug: ZT006
Participants will receive a daily dose of ZT006
Participants will receive a daily dose of placebo of ZT006
Participants will receive a weekly dose of ZT006
Participants will receive a weekly dose of ZT006
Participants will receive a weekly dose of ZT006
Participants will receive a weekly dose of ZT006
Change in body weight relative to baseline
Percentage-point
Time frame: Percentage-point from baseline to end of treatment (week 28)of the main study
Rate of treatment-emergent adverse events in the extension period
Summarized from adverse event reporting in %
Time frame: From week 28 to week 45
Rate of serious adverse events in the extension period
Summarized from adverse event reporting in %
Time frame: From week 28 to week 45
Proportion of participants who achieved body weight reduction greater than or equal to 5% at week 28
Proportion of participants in %
Time frame: From baseline to end of treatment in the main study (week 28)
Proportion of participants who achieved body weight reduction greater than or equal to 10% at week 28
Proportion of participants in %
Time frame: From baseline to end of treatment in the main study (week 28)
Proportion of participants who achieved body weight reduction greater than or equal to 15% at week 28
Proportion of participants in %
Time frame: From baseline to end of treatment in the main study(week 28)
Change in body weight
Measured in kg
Time frame: From baseline to end of treatment in the main study (week 28)
Change in waist circumference
Measured in cm
Time frame: From baseline to end of treatment in the main study (week 28)
Change in body mass index (BMI)
Measured in kg/m²（ Body weight in kilogram divided by the square of height in meter ）
Time frame: From baseline to end of treatment in the main study (week 28)
Rate of treatment-emergent adverse events
Summarized from adverse event reporting in %
Time frame: From baseline to end of the main study (week 33)
Rate of serious adverse events
Summarized from adverse event reporting in %
Time frame: From baseline to end of the main study (week 33)
Proportion of participants with positive anti-ZT006 antibody
Summarized in %
Time frame: From baseline to end of treatment in the main study (week 33)
Change in body weight relative to baseline in the extension period
Percentage point
Time frame: From week 28 to week 40
Change in body weight
Measured in kg
Time frame: From week 28 to week 40
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 12 months is close to that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing QL Biopharmaceutical Co.,Ltd →